首页|miRNA-99b、LL-37、IP-10在耐多药肺结核患者中表达及早期疗效预测价值

miRNA-99b、LL-37、IP-10在耐多药肺结核患者中表达及早期疗效预测价值

扫码查看
目的 分析微小RNA-99b(miRNA-99b)、抗菌肽LL-37、干扰素-γ诱导蛋白10(IP-10)在耐多药肺结核(MDR-PTB)患者中表达及早期疗效预测价值。方法 研究纳入医院2022年11月-2024年2月临床收治MDR-PTB患者108例为MDR-PTB组,Bandim TBscore评分法将其划分为轻度组(n=71)与中-重度组(n=37);纳入同期非耐药肺结核患者(DS-PTB)87例为DS-PTB组,健康体检志愿者90例为健康对照组,检测、评估组间miRNA-99b、LL-37、IP-10表达水平及治疗8周后临床疗效,采用Pearson评估miRNA-99b、LL-37、IP-10表达水平与MDR-PTB患者临床疗效相关性,指标预测价值行多因素Logistic回归,作ROC曲线分析模型预测价值。结果 MDR-PTB组miRNA-99b、LL-37、IP-10均高于DS-PTB组与健康对照组(P<0。05),且DS-PTB 组 miRNA-99b、LL-37、IP-10 高于健康对照组(P<0。05);MDR-PTB 组内,中-重度组 miRNA-99b、LL-37、IP-10表达水平均高于轻度组(P<0。05);治疗4周、治疗8周后,MDR-PTB患者miRNA-99b、LL-37、1P-10均低于治疗前(P<0。05);108例MDR-PTB患者经8周治疗后临床有效率为88。89%;miRNA-99b、LL-37、IP-10 均与有效率呈负相关关系(r=-0。693、-0。706、-0。497,P<0。05);miRNA-99b、LL-37、IP-10 高水平表达为MDR-PTB发生发展独立危险因素,有统计学意义(P<0。05),ROC曲线分析显示,miRNA-99b、LL-37、IP-10联合检测 AUC 为 0。937(95%CI:0。863-0。974)高于单一检测结果(Z=7。691、7。069、8。068,P 均<0。001);且联合检测敏感度(96。91%)与特异度(96。34%)均最高。结论 miRNA-99b、LL-37、IP-10高水平表达参与MDR-PTB发生与发展,三项联合在MDR-PTB患者早期疗效预测中应用价值高。
The expression and early efficacy prediction value of miRNA-99b,LL-37,and IP-10 in multidrug-resistant pulmonary tuberculosis patients
Objective To analyze the expression of micro RNA-99B(miRNA-99b),antimicrobial peptide LL-37,interferon-gamma-induced protein 10(IP-10)in patients with multidrug-resistant pulmonary tuberculosis(MDR-PTB)and the value of early curative effect prediction.Methods A total of 108 MDR-PTB patients admit-ted to the hospital from November 2022 to February 2024 were classified as MDR-PTB group and were divided into mild group(n=71)and moderate to severe group(n=37)by Bandim TBscore.Eighty-seven patients with non-drug-resistant tuberculosis(DS-TB)were included in the DS-TB group and 90 healthy volunteers were included in the healthy control group.The expression levels of miRNA-99b,LL-37,and IP-10 between the groups were detected and evaluated,and the clinical efficacy after 8 weeks of treatment was also evaluated.Pearson was used to evaluate the correlation between the expression levels of miRNA-99b,LL-37,and IP-10 and the clinical efficacy of MDR-PTB patients.The predictive value of indicators was evaluated by multivariate Logistic regression,and the predictive value of the ROC curve analysis model was performed.Results The miRNA-99b,LL-37,and IP-10 levels in the MDR-PTB group were higher than those in the DS-TB group and healthy control group(P<0.05),and the miRNA-99b,LL-37,and IP-10 levels in the DS-TB group were higher than those in the healthy control group(P<0.05);In the MDR-PTB group,the expression levels of miRNA-99b,LL-37,and IP-10 in the moderate to the severe group were higher than those in the mild group(P<0.05);After 4 weeks of treatment and 8 weeks of treatment,the miRNA-99b,LL-37,and IP-10 levels in MDR-PTB patients were lower than before treatment(P<0.05);After 8 weeks of treatment,the clinical effective rate of 108 MDR-PTB patients was 88.89%;MiRNA-99b,LL-37,and IP-10 are all negatively correlated with efficacy(r=-0.693,-0.706,-0.497,P<0.05);High levels of expression of miR-NA-99b,LL-37,and IP-10 were independent risk factors for the occurrence and development of MDR-PTB,with sta-tistical significance(P<0.05).ROC curve analysis showed that the combined detection of miRNA-99b,LL-37,and IP-10 had an AUC of 0.937(95%CI:0.863-0.974)(Z=7.691,7.069,8.068,P<0.001),which was higher than that of a single detection result,and the combined detection had the highest sensitivity(96.91%)and specificity(96.34%).Conclusion High levels of miRNA-99b,LL-37,and IP-10 expression are involved in the occurrence and development of MDR-PTB,and the combination of these three factors has high application value in early efficacy prediction of MDR-PTB patients.

miRNA-99bLL-37IP-10Multidrug resistant pulmonary tuberculosisEarly efficacypre-dictive value

周贵忠、黄远江、翁敏华、张振云

展开 >

570216 海南海口,海南医学院第二附属医院感染病与热带病科

miRNA-99b LL-37 IP-10 耐多药肺结核 早期疗效 预测价值

2025

临床肺科杂志
安徽医科大学 解放军第105医院

临床肺科杂志

影响因子:1.42
ISSN:1009-6663
年,卷(期):2025.30(1)